HK1155170A1 - Pyridine compounds - Google Patents
Pyridine compoundsInfo
- Publication number
- HK1155170A1 HK1155170A1 HK11109503.8A HK11109503A HK1155170A1 HK 1155170 A1 HK1155170 A1 HK 1155170A1 HK 11109503 A HK11109503 A HK 11109503A HK 1155170 A1 HK1155170 A1 HK 1155170A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyridine compounds
- pyridine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7305508P | 2008-06-17 | 2008-06-17 | |
PCT/GB2009/050675 WO2009153589A1 (en) | 2008-06-17 | 2009-06-15 | Pyridine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1155170A1 true HK1155170A1 (en) | 2012-05-11 |
Family
ID=40896110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11109503.8A HK1155170A1 (en) | 2008-06-17 | 2011-09-08 | Pyridine compounds |
Country Status (18)
Country | Link |
---|---|
US (1) | US8569298B2 (ru) |
EP (1) | EP2303861B1 (ru) |
JP (1) | JP5551689B2 (ru) |
KR (1) | KR101695501B1 (ru) |
CN (1) | CN102124000B (ru) |
AU (1) | AU2009261764B2 (ru) |
BR (1) | BRPI0914927B8 (ru) |
CA (1) | CA2726508C (ru) |
CR (1) | CR11854A (ru) |
DO (1) | DOP2010000390A (ru) |
EA (1) | EA020807B1 (ru) |
EC (1) | ECSP10010695A (ru) |
ES (1) | ES2472323T3 (ru) |
HK (1) | HK1155170A1 (ru) |
IL (1) | IL209727A0 (ru) |
MX (1) | MX2010014057A (ru) |
WO (1) | WO2009153589A1 (ru) |
ZA (1) | ZA201100388B (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140155410A1 (en) * | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
JO3067B1 (ar) * | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
WO2010068947A2 (en) * | 2008-12-12 | 2010-06-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Nuclear export inhibitors of topoisomerase ii alpha |
PL2464645T3 (pl) | 2009-07-27 | 2017-12-29 | Gilead Sciences, Inc. | Skondensowane heterocykliczne związki jako modulatory kanałów jonowych |
CN103003264B (zh) | 2010-05-21 | 2014-08-06 | 切米利亚股份公司 | 嘧啶衍生物 |
CN103313697B (zh) | 2010-06-29 | 2016-06-01 | 维瑞斯特姆股份有限公司 | 激酶抑制剂的口服制剂 |
AU2011280031B2 (en) * | 2010-06-30 | 2015-09-10 | Verastem, Inc. | Synthesis and use of Kinase inhibitors |
CN103096977B (zh) | 2010-07-02 | 2017-02-15 | 吉利德科学公司 | 作为离子通道调节剂的稠杂环化合物 |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
CN103476413B (zh) * | 2011-01-26 | 2016-03-16 | 葛兰素史密斯克莱知识产权有限公司 | 组合 |
US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
JP5886411B2 (ja) | 2011-03-24 | 2016-03-16 | ノビガ・リサーチ・エービーNoviga Research AB | 新規のピリミジン誘導体 |
MX361350B (es) | 2011-05-10 | 2018-12-04 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal de sodio. |
NO3175985T3 (ru) | 2011-07-01 | 2018-04-28 | ||
TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
SG10201507714XA (en) | 2012-03-16 | 2015-10-29 | Axikin Pharmaceuticals Inc | 3,5-diaminopyrazole kinase inhibitors |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
WO2015193765A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Substituted dihydroisoquinolinone compounds |
US9442005B2 (en) | 2014-07-30 | 2016-09-13 | Corning Optical Communications LLC | Non-contact methods of measuring insertion loss in optical fiber connectors |
CN107250116B (zh) | 2014-12-23 | 2020-10-27 | 艾士盟医疗公司 | 3,5-二氨基吡唑激酶抑制剂 |
GB201510010D0 (en) | 2015-06-09 | 2015-07-22 | King S College London | PDD and BPD compounds |
JP2018519327A (ja) | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドVerastem,Inc. | 治療用組成物、組合せ物および使用の方法 |
GB201514928D0 (en) | 2015-08-21 | 2015-10-07 | King S College London | PDD compounds |
US20180339985A1 (en) | 2015-08-21 | 2018-11-29 | Femtogenix Limited | Pdd compounds |
IL302719A (en) | 2018-02-28 | 2023-07-01 | Basf Se | Use of N-functional alkoxy pyrazole compounds as nitrification inhibitors |
WO2019166558A1 (en) | 2018-02-28 | 2019-09-06 | Basf Se | Use of pyrazole propargyl ethers as nitrification inhibitors |
RU2020133451A (ru) | 2018-03-12 | 2022-04-12 | Инститьют Насьонал Де Ла Санте Et De La Решерш Медикаль (Инсерм) | Применение терапевтически эффективной комбинации химиотерапиии и ингибитора контрольной точки иммунного ответа с миметиком ограничения калорийности для лечения рака |
CN108912095B (zh) * | 2018-08-09 | 2019-08-20 | 广州安岩仁医药科技有限公司 | 苯并咪唑类化合物及其制备方法和应用 |
JP2022552019A (ja) | 2019-10-18 | 2022-12-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 病的血管障害の治療のための作用物質としての3-フェニルスルホニル-キノリン誘導体 |
AR125955A1 (es) | 2021-05-21 | 2023-08-30 | Basf Se | Uso de un compuesto de alcoxi pirazol n-funcionalizado como inhibidor de nitrificación |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
DE10336184A1 (de) | 2003-08-07 | 2005-02-24 | Bayer Materialscience Ag | Neue Katalysatoren für die selektive Isocyanatdimerisierung |
WO2005016894A1 (en) * | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
BRPI0512342A (pt) | 2004-06-21 | 2008-03-04 | Pharmacia & Upjohn Co Llc | métodos para aumento ósseo |
GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
ATE519759T1 (de) | 2004-12-30 | 2011-08-15 | Exelixis Inc | Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren |
US8722884B2 (en) * | 2005-12-01 | 2014-05-13 | Verastem, Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
JP4332590B2 (ja) | 2005-12-21 | 2009-09-16 | ファイザー・プロダクツ・インク | 異常細胞増殖を治療するためのピリミジン誘導体 |
PL2091918T3 (pl) | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
EP2134689B1 (en) * | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
WO2009012283A1 (en) * | 2007-07-17 | 2009-01-22 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
-
2009
- 2009-06-15 AU AU2009261764A patent/AU2009261764B2/en active Active
- 2009-06-15 JP JP2011514125A patent/JP5551689B2/ja active Active
- 2009-06-15 CN CN200980132565.2A patent/CN102124000B/zh active Active
- 2009-06-15 ES ES09766150.8T patent/ES2472323T3/es active Active
- 2009-06-15 EA EA201100032A patent/EA020807B1/ru not_active IP Right Cessation
- 2009-06-15 BR BRPI0914927A patent/BRPI0914927B8/pt active IP Right Grant
- 2009-06-15 CA CA2726508A patent/CA2726508C/en active Active
- 2009-06-15 WO PCT/GB2009/050675 patent/WO2009153589A1/en active Application Filing
- 2009-06-15 KR KR1020117001022A patent/KR101695501B1/ko active IP Right Grant
- 2009-06-15 US US12/999,025 patent/US8569298B2/en active Active
- 2009-06-15 EP EP09766150.8A patent/EP2303861B1/en active Active
- 2009-06-15 MX MX2010014057A patent/MX2010014057A/es active IP Right Grant
-
2010
- 2010-12-02 IL IL209727A patent/IL209727A0/en unknown
- 2010-12-17 CR CR11854A patent/CR11854A/es not_active Application Discontinuation
- 2010-12-17 EC EC2010010695A patent/ECSP10010695A/es unknown
- 2010-12-17 DO DO2010000390A patent/DOP2010000390A/es unknown
-
2011
- 2011-01-14 ZA ZA2011/00388A patent/ZA201100388B/en unknown
- 2011-09-08 HK HK11109503.8A patent/HK1155170A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2472323T3 (es) | 2014-06-30 |
CN102124000B (zh) | 2014-09-17 |
CA2726508A1 (en) | 2009-12-23 |
EA201100032A1 (ru) | 2012-01-30 |
EA020807B1 (ru) | 2015-01-30 |
KR20110023884A (ko) | 2011-03-08 |
JP5551689B2 (ja) | 2014-07-16 |
JP2011524411A (ja) | 2011-09-01 |
BRPI0914927B8 (pt) | 2021-05-25 |
US20110166139A1 (en) | 2011-07-07 |
ZA201100388B (en) | 2011-10-26 |
AU2009261764A1 (en) | 2009-12-23 |
EP2303861A1 (en) | 2011-04-06 |
KR101695501B1 (ko) | 2017-01-11 |
BRPI0914927B1 (pt) | 2020-10-06 |
CN102124000A (zh) | 2011-07-13 |
US8569298B2 (en) | 2013-10-29 |
AU2009261764B2 (en) | 2013-01-10 |
CA2726508C (en) | 2016-06-07 |
BRPI0914927A2 (pt) | 2017-06-20 |
CR11854A (es) | 2011-02-25 |
MX2010014057A (es) | 2011-03-21 |
IL209727A0 (en) | 2011-02-28 |
EP2303861B1 (en) | 2014-04-23 |
DOP2010000390A (es) | 2011-01-15 |
ECSP10010695A (es) | 2011-01-31 |
WO2009153589A1 (en) | 2009-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1155170A1 (en) | Pyridine compounds | |
GB0807862D0 (en) | Compounds | |
IL206276A0 (en) | Pyridine derivatives | |
GB0804702D0 (en) | Compounds | |
GB0809776D0 (en) | Compounds | |
IL205666A0 (en) | Pyridine compounds | |
GB0807103D0 (en) | Compounds | |
GB0800367D0 (en) | Compounds | |
EP2301922A4 (en) | pyridone | |
GB0807910D0 (en) | Compounds | |
GB0801220D0 (en) | Compounds | |
GB0801265D0 (en) | Compounds | |
GB0805504D0 (en) | Compounds | |
GB0808669D0 (en) | Compounds | |
GB0807911D0 (en) | Compounds | |
GB0807415D0 (en) | Compounds | |
GB0807047D0 (en) | Compounds | |
GB0806449D0 (en) | Compounds | |
GB0806448D0 (en) | Compounds | |
GB0806083D0 (en) | Compounds | |
GB0805993D0 (en) | Compounds | |
GB0805815D0 (en) | Compounds | |
GB0808123D0 (en) | Compounds | |
GB0805498D0 (en) | Compounds | |
GB0810118D0 (en) | Compounds |